Personalized cell therapy takes on Hard-to-Treat tumors
NCT ID NCT07294872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of chemotherapy. The goal is to see if this approach is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TIL)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The treatment involves intensive chemotherapy beforehand and may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center
Chengdu, China